Skip to content
Search

Latest Stories

Nine new medicines added to ‘DND’ list

Nine more new products have been classed as ‘Drugs for which Discount is Not Deducted’ (DND list) from 1 July 2022, announced Department of Health and Social Care (DHSC).

This takes the total number of products granted DND status over the past 2 years to over 500 following checks made by the Pharmaceutical Services Negotiating Committee.


The Committee had made an application to DHSC and NHSBSA for the following  9 products to be added to the DND list of Individual items to which the discount deduction scale will no longer apply from July 2022:

  • Fludrocortisone 50micrograms/5ml oral suspension (Group)
  • Lorazepam 1mg/5ml oral suspension (Group)
  • Lorazepam 500micrograms/5ml oral suspension (Group)
  • Zopiclone 3.75mg/5ml oral solution (Group)
  • Zopiclone 7.5mg/5ml oral solution (Group)
  • GA explore5 oral powder 12.5g sachets
  • HCU explore5 oral powder 12.5g sachets
  • MSUD explore5 oral powder 12.5g sachets
  • TYR explore5 oral powder 12.5g sachets

The DND list is updated monthly by the DHSC and includes grouped and individual items. Individual items are separately listed in Part II of the Drug Tariff.

Any items covered by the ‘Group Items’ heading are not listed again individually in Part II. Contractors can also check the Actual Medicinal Product (AMP) listing on Dictionary of Medicines and Devices (dm+d) to identify whether a product meets the DND criteria.

Group items

Any products that are covered by one or more of the Group items categories below are reimbursed without any discount deduction applied.

  • Cold Chain Storage (ALL)
  • Schedule 1, 2 or 3 Controlled Drugs: Products containing drugs listed in Schedules 1, 2 and 3 of the Misuse of Drugs Regulation 2001
  • Cytotoxic or Cytostatic item (ALL):
  • Immunoglobulins (ALL)
  • Insulins for injection (ALL)
  • Vaccines and antisera (ALL)
  • Unlicensed medicines: ‘Specials’ not listed in Part VIIIB where the product has been sourced from a supplier holding a MHRA specials or importers licence (prescriptions must be endorsed with invoice price less discount/rebate)
  • Hazardous chemicals

Individual items 

Products that do not are covered by one or more of the Group item categories above must fulfil all three of the following criteria to qualify for entry to the DND list.

  • the manufacturer(s), AAH and Alliance do not offer pharmacy contractors a discount
  • fewer than 500,000 items per year are dispensed of the product
  • average net ingredient cost (NIC) per item is more than £50

More For You

ABPI and government fast-track VPAG scheme review to address high medicine payment rates

The 2025 VPAG payment rate for newer medicines has been set at 22.9 per cent.

Photo credit: gettyimages

Review of 2024 VPAG scheme to be completed by June

The Association of the British Pharmaceutical Industry (ABPI) and the government have agreed to bring forward a planned review of the 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG), originally scheduled for autumn 2025.

The review is expected to be completed in June 2025, aligning with the anticipated release of the government’s 10-year NHS Plan and the Life Sciences Sector Plan as part of the broader industry strategy this summer.

Keep ReadingShow less
Majority of Brits neglect consistent skincare routine,  survey finds

On average, Brits go to bed without washing their face twice a week.

Photo credit: gettyimages

Skincare: One in five Brits go to bed without washing their face daily, survey finds

Nearly two-thirds of Brits (60 per cent) neglect a consistent skincare routine,with almost one in five going to bed without washing their face daily, according to a new survey by consumer health company Kenvue.

The UK-wide survey of 2,000 people revealed that one-third of respondents (34 per cent) spend five minutes or less on their daily skincare routine. On average, Brits go to bed without washing their face twice a week.

Keep ReadingShow less
Risk of pharmacy closures remains despite record funding uplift

Community pharmacy sector remains in a fragile position as the funding gap is still significant, says CCA.

gettyimages

Pharmacy closures still a risk as funding deal fails to cover costs – warns CCA

The community pharmacy sector has secured the largest funding uplift across the NHS, yet concerns remain that it may not be enough to prevent further closures and service reductions.

Following a six-week consultation with Community Pharmacy England (CPE), the government has approved a £3.073 billion funding package for 2025/26, supplemented by an additional £215 million to support Pharmacy First and other Primary Care Recovery Plan services.

Keep ReadingShow less
Independent Prescribing: Government aims to complete pathfinder programme evaluation by autumn 2025

Pharmacist prescribers at 210 ‘pathfinder’ sites were allowed to trial prescribing models within integrated primary care services.

Photo credit: gettyimages

Independent prescribing: Pathfinder programme evaluation to be completed by autumn, says Kinnock

Health minister Stephen Kinnock has revealed that the evaluation of the Community Pharmacy Independent Prescribing Pathfinder Programme could be completed by Autumn 2025.

Kinnock was responding to a question from James Naish, Labour MP for Rushcliffe, who asked what steps the minister was taking to ensure continued support for the Pathfinder Programme and independent prescribing to maximise direct prescribing capacity in England.

Keep ReadingShow less
NHS pharmacy funding not enough 2025: £3.073B deal with £1.99B gap fuels reform debate.

Funding alone isn’t going to be enough to save community pharmacy

Photo credit: gettyimages

New funding contract ‘not enough’ to release the sector from financial blackhole

After almost a year without an agreement, a new funding contract for community pharmacy was finally announced yesterday (31 March).

The settlement raises the baseline annual funding for the Community Pharmacy Contractual Framework (CPCF) in 2025/26 to £3.073 billion, with an additional £215 million secured to continue Pharmacy First and other Primary Care Recovery Plan services.

Keep ReadingShow less